Wang Li, Hu Jihong
Public Health School, Gansu University of Chinese Medicine, Lanzhou, China.
Teaching Experiment and Training Center, Gansu University of Chinese Medicine, Lanzhou, China.
Front Cardiovasc Med. 2024 Jul 18;11:1410623. doi: 10.3389/fcvm.2024.1410623. eCollection 2024.
The gut microbiota plays a pivotal role in both maintaining human health and in the pathogenesis of diseases. Recent studies have brought to light the significant correlation between gut microbiota and hypertension, particularly focusing on its role in the development and advancement of SSH, a subtype characterized by elevated blood pressure in response to high salt consumption. The complexity of SSH's etiology is notable, with dysbiosis of the gut microbiome identified as a crucial contributing factor. The gut microbiota participates in the occurrence and development of SSH by affecting the host's immune system, metabolic function, and neuromodulation. Investigations have demonstrated that the gut microbes regulate the development of SSH by regulating the TH17 axis and the activity of immune cells. Moreover, microbial metabolites, such as short-chain fatty acids, are implicated in blood pressure regulation and affect the development of SSH. There is evidence to show that the composition of the gut microbiome can be altered through prebiotic interventions so as to prevent and treat SSH. This review aims to concisely sum up the role of gut microbiota in SSH and to discuss pertinent therapeutic strategies and clinical implications, thereby providing a valuable reference for further research and clinical practice in this area.
肠道微生物群在维持人类健康和疾病发病机制中都起着关键作用。最近的研究揭示了肠道微生物群与高血压之间的显著关联,尤其关注其在盐敏感性高血压(SSH)的发生和发展中的作用,SSH是一种因高盐摄入导致血压升高的亚型。SSH病因复杂,肠道微生物群失调被认为是一个关键因素。肠道微生物群通过影响宿主的免疫系统、代谢功能和神经调节参与SSH的发生和发展。研究表明,肠道微生物通过调节TH17轴和免疫细胞活性来调控SSH的发展。此外,微生物代谢产物,如短链脂肪酸,也参与血压调节并影响SSH的发展。有证据表明,可通过益生元干预改变肠道微生物群的组成,从而预防和治疗SSH。本综述旨在简要总结肠道微生物群在SSH中的作用,并讨论相关治疗策略和临床意义,从而为该领域的进一步研究和临床实践提供有价值的参考。